Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study.

Hirokazu KagawaNobuyoshi KosakaYuria KiuchiKota KatsumiRyotaro YamaguchiYushi SuharaKentaro YoshiharaYuma GotoIbuki SadakaneYuji YataShun SaitoShiro KurawakiShino AjisakaKeiichiro MiyajimaKazuhiro TakahashiKosuke IwataniYu ImaiKeigo SakanakaMinoru NakazonoTakashi KurauchiSotaro KayanoHajime OnumaKoichi AikawaTakafumi YanagisawaKojiro TashiroShunsuke TsuzukiAkira FurutaJun MikiTakahiro Kimuranull null

Published in: International journal of clinical oncology (2023)

In total, 44.8% of patients were candidates for adjuvant immunotherapy. In addition to pathological T and N status, LVI was a significant predictor of survival, and may thus play a pivotal role in the selection of patients eligible for adjuvant immunotherapy.

Keyphrases

end stage renal disease
early stage
ejection fraction
prognostic factors
type diabetes
clinical trial
patient reported outcomes
cross sectional